ClinicalTrials.gg
CompletedNCT01652703AMG145Updated Nov 28, 2018Results posted

A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects

A Phase 2 interventional study of Evolocumab and Placebo in Hypercholesterolemia and High Risk for Cardiovascular Events, sponsored by Amgen. Completed at 42 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-11-28.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
17th of 36
310 · median 308
Started
2012
with 3 others
Phase 2
5 of 36
none open now
Registered
8th of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 17th largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 2, and was the 8th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

The primary objective is to evaluate the effect of 12 weeks of subcutaneous evolocumab every 2 weeks or every 4 weeks, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) when used in addition to statin therapy in Japanese adults with hypercholesterolemia and high cardiovascular risk.

03

Conditions studied

  • Hypercholesterolemia and High Risk for Cardiovascular Events

Keywords

  • Japanese, hypercholesterolemia, high risk for cardiovascular events
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Japanese adult, on statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks, fasting LDL-C greater than or equal to 115 mg/dL (3.0 mmol/L), fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L); Exclusion Criteria: (NYHA) class III or IV, poorly controlled hypertension, recently diagnosed or poorly controlled type 2 diabetes, last known \< 30%, myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), stroke, planned cardiac surgery or revascularization within 6 months of randomization, uncontrolled cardiac arrhythmia.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
310 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.

    Other: Placebo

  • Placebo comparator
    Placebo Q4W

    Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.

    Other: Placebo

  • Experimental
    Evolocumab 70 mg Q2W

    Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 140 mg Q2W

    Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 280 mg Q4W

    Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 420 mg Q4W

    Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha

  • OtherPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

    LDL-C was measured using ultracentrifugation.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

    LDL-C was measured using ultracentrifugation.

    Time frame: Baseline and Week 12

  2. Percentage of Participants With an LDL-C Response at Week 12

    An LDL-C response was defined as LDL-C \< 70 mg/dL (1.8 mmol/L) at Week 12. LDL-C was measured using ultracentrifugation.

    Time frame: Week 12

  3. Percent Change From Baseline to Week 12 in Non-HDL-C

    Time frame: Baseline and Week 12

  4. Percent Change From Baseline to Week 12 in Apolipoprotein B

    Time frame: Baseline and Week 12

  5. Percent Change From Baseline to Week 12 in VLDL-C

    Time frame: Baseline and Week 12

  6. Percent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio

    Time frame: Baseline and Week 12

  7. Percent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio

    Time frame: Baseline and Week 12

07

Results

Posted Oct 5, 2015

Participant flow

Japanese men or women ≥ 20 to ≤ 80 years of age and who were at high risk for cardiovascular events, on a stable dose of an approved statin (with or without ezetimibe) and fasting low-density lipoprotein cholesterol (LDL-C) ≥ 115 mg/dL. First patient enrolled on 10 July 2012; last patient enrolled 19 February 2013.

Participant flow — Overall Study
MilestonePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4W
Started525150525253
Received treatment525049525153
Completed525047505151
Not completed013212
Withdrew: Withdrawal by subject013101
Withdrew: Other000111

Outcome measures

PrimaryPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

LDL-C was measured using ultracentrifugation.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12-2.71 ± 2.160.05 ± 2.32-55.56 ± 2.23-71.32 ± 2.16-58.10 ± 2.33-63.89 ± 2.27
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -68.61 · 95% CI -74.51 to -62.71Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -52.85 · 95% CI -58.84 to -46.86Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -63.94 · 95% CI -70.23 to -57.66Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -58.16 · 95% CI -64.51 to -51.81Placebo is the reference
SecondaryChange From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

LDL-C was measured using ultracentrifugation.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
mg/dLPlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4W
Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12-1.8 ± 3.60.8 ± 3.4-77.2 ± 3.7-98.0 ± 3.6-79.9 ± 3.4-87.4 ± 3.3
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -96.3 · 95% CI -106.0 to -86.5Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -75.5 · 95% CI -85.4 to -65.5Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -88.2 · 95% CI -97.4 to -79.0Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -80.7 · 95% CI -90.0 to -71.4Placebo is the reference
SecondaryPercentage of Participants With an LDL-C Response at Week 12

An LDL-C response was defined as LDL-C \< 70 mg/dL (1.8 mmol/L) at Week 12. LDL-C was measured using ultracentrifugation.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an LDL-C Response at Week 12
percentage of participantsPlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4W
Percentage of Participants With an LDL-C Response at Week 120.0 ± 3.60.0 ± 3.466.0 ± 3.796.0 ± 3.680.4 ± 3.482.4 ± 3.3
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Regression, Logistic · p = <0.001 (Testing based on a significance level of 0.05.) · Odds ratio (or): 1945.68 · 95% CI 89.64 to 42232.63Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · Regression, Logistic · p = <0.001 (Testing based on a significance level of 0.05.) · Odds ratio (or): 281.13 · 95% CI 14.74 to 5360.92Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · Regression, Logistic · p = <0.001 (Testing based on a significance level of 0.05.) · Odds ratio (or): 536.45 · 95% CI 28.37 to 10143.40Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · Regression, Logistic · p = <0.001 (Testing based on a significance level of 0.05.) · Odds ratio (or): 595.59 · 95% CI 31.11 to 11402.67Placebo is the reference
SecondaryPercent Change From Baseline to Week 12 in Non-HDL-C
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Non-HDL-C
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline to Week 12 in Non-HDL-C-2.20 ± 1.940.55 ± 2.17-51.66 ± 2.00-64.76 ± 1.94-53.00 ± 2.17-57.53 ± 2.12
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -62.56 · 95% CI -67.85 to -57.27Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -49.46 · 95% CI -54.83 to -44.08Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -58.08 · 95% CI -63.93 to -52.22Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -53.54 · 95% CI -59.46 to -47.63Placebo is the reference
SecondaryPercent Change From Baseline to Week 12 in Apolipoprotein B
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Apolipoprotein B
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline to Week 12 in Apolipoprotein B-0.90 ± 1.820.22 ± 2.02-47.65 ± 1.88-61.59 ± 1.82-47.16 ± 2.03-53.22 ± 1.98
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -60.69 · 95% CI -65.67 to -55.72Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -46.75 · 95% CI -51.80 to -41.70Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -53.44 · 95% CI -58.91 to -47.97Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -47.37 · 95% CI -52.90 to -41.85Placebo is the reference
SecondaryPercent Change From Baseline to Week 12 in VLDL-C
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in VLDL-C
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline to Week 12 in VLDL-C8.23 ± 8.557.26 ± 6.87-16.02 ± 8.74-26.26 ± 8.44-13.56 ± 6.80-22.56 ± 6.71
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = 0.004 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -34.49 · 95% CI -57.71 to -11.26Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = 0.044 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -24.25 · 95% CI -47.83 to -0.68Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = 0.002 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -29.82 · 95% CI -48.32 to -11.32Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = 0.028 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -20.82 · 95% CI -39.41 to -2.22Placebo is the reference
SecondaryPercent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio-4.82 ± 1.911.19 ± 2.09-42.04 ± 1.98-51.81 ± 1.91-44.11 ± 2.10-45.47 ± 2.05
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -46.98 · 95% CI -52.21 to -41.76Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -37.22 · 95% CI -42.52 to -31.91Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -46.66 · 95% CI -52.32 to -41.00Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -45.30 · 95% CI -51.02 to -39.58Placebo is the reference
SecondaryPercent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio-3.18 ± 2.121.44 ± 2.21-50.71 ± 2.19-64.53 ± 2.12-50.79 ± 2.22-56.31 ± 2.16
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -61.35 · 95% CI -67.14 to -55.56Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -47.53 · 95% CI -53.41 to -41.65Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -57.75 · 95% CI -63.73 to -51.77Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -52.22 · 95% CI -58.27 to -46.18Placebo is the reference

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W—0/52 (0%)6/52 (11.5%)
Placebo Q4W—0/50 (0%)6/50 (12%)
Evolocumab Q2W 70 MG—0/49 (0%)10/49 (20.4%)
Evolocumab Q2W 140 MG—1/52 (1.9%)9/52 (17.3%)
Evolocumab Q4W 280 MG—1/51 (2%)12/51 (23.5%)
Evolocumab Q4W 420 MG—2/53 (3.8%)8/53 (15.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo Q2WPlacebo Q4WEvolocumab Q2W 70 MGEvolocumab Q2W 140 MGEvolocumab Q4W 280 MGEvolocumab Q4W 420 MG
ArteriosclerosisVascular disorders0/520/500/490/521/510/53
FractureInjury, poisoning and procedural complications0/520/500/491/520/510/53
Carcinoid tumour of the caecumNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/520/500/490/520/511/53
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/520/500/490/520/511/53
Most frequent other events
Most frequent other events
EventPlacebo Q2WPlacebo Q4WEvolocumab Q2W 70 MGEvolocumab Q2W 140 MGEvolocumab Q4W 280 MGEvolocumab Q4W 420 MG
NasopharyngitisInfections and infestations6/526/5010/499/5212/518/53

Baseline characteristics

Full analysis set (all randomized participants who received at least 1 dose of investigational product).

Age, Continuous
Age, Continuous(years)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4WTotal
Mean60.2 ± 10.160.9 ± 9.864.1 ± 9.760.8 ± 9.261.6 ± 9.661.3 ± 9.961.5 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4WTotal
Female161424202317114
Male363625322836193
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4WTotal
American Indian or Alaska Native0000000
Asian525049525153307
Black or African American0000000
Native Hawaiian or Other Pacific Islander0000000
White0000000
Stratification Factor: LDL Level
Stratification Factor: LDL Level(participants)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4WTotal
< 130 mg/dL17171517151798
≥ 130 mg/dL353334353636209
Stratification Factor: Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)
Stratification Factor: Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)(participants)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4WTotal
No484747494749287
Yes43234420
LDL-C Concentration
LDL-C Concentration(mg/dL)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4WTotal
Mean144.4 ± 18.1141.8 ± 23.4143.6 ± 20.6140.7 ± 23.3141.0 ± 21.2139.7 ± 18.8141.8 ± 20.9
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4WTotal
Mean171.3 ± 23.0168.7 ± 26.1170.6 ± 27.2166.3 ± 26.2165.5 ± 24.4166.7 ± 23.5168.2 ± 25.0
Apolipoprotein B Concentration
Apolipoprotein B Concentration(mg/dL)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 420 mg Q4WTotal
Mean114.6 ± 15.4112.5 ± 16.6113.1 ± 19.2109.4 ± 16.0109.6 ± 16.9109.8 ± 15.9111.5 ± 16.7

3 further baseline measures are reported on the registry.

08

Study locations

42 sites
  • Research Site
    Nagoya-shi, Aichi 454-0933, Japan
  • Research Site
    Nagoya-shi, Aichi 455-8530, Japan
  • Research Site
    Nagoya-shi, Aichi 462-0825, Japan
  • Research Site
    Fukui-shi, Fukui 910-0067, Japan
  • Research Site
    Fukui-shi, Fukui 910-0803, Japan
  • Research Site
    Fukui-shi, Fukui 910-0837, Japan
  • Research Site
    Kasuga-shi, Fukuoka 816-0864, Japan
  • Research Site
    Gifu-shi, Gifu 500-8384, Japan
  • Research Site
    Fujioka-shi, Gunma 375-0015, Japan
  • Research Site
    Maebashi-shi, Gunma 371-0022, Japan
  • Research Site
    Maebashi-shi, Gunma 371-0046, Japan
  • Research Site
    Takasaki-shi, Gunma 370-0829, Japan
  • Research Site
    Kawani-shi, Hyogo 666-0125, Japan
  • Research Site
    Kobe-shi, Hyogo 657-0068, Japan
  • Research Site
    Hitachi-shi, Ibaraki 317-0077, Japan
  • Research Site
    Koga-shi, Ibaraki 306-0041, Japan
  • Research Site
    Mito-shi, Ibaraki 311-4198, Japan
  • Research Site
    Komatsu-shi, Ishikawa 923-8560, Japan
  • Research Site
    Takamatsu-shi, Kagawa 760-8557, Japan
  • Research Site
    Kochi-shi, Kochi 781-8555, Japan
  • Research Site
    Kumamoto-shi, Kumamoto 860-8556, Japan
  • Research Site
    Kyoto-shi, Kyoto 613-0911, Japan
  • Research Site
    Kyoto-shi, Kyoto 615-8125, Japan
  • Research Site
    Ina-shi, Nagano 396-8555, Japan
  • Research Site
    Matsumoto-shi, Nagano 390-0848, Japan
  • Research Site
    Suwa-shi, Nagano 392-8510, Japan
  • Research Site
    Ibaraki-shi, Osaka 567-0876, Japan
  • Research Site
    Suita-shi, Osaka 565-0871, Japan
  • Research Site
    Toyonaka-shi, Osaka 560-0082, Japan
  • Research Site
    Hanyu-shi, Saitama 348-8505, Japan
  • Research Site
    Sayama-shi, Saitama 350-1305, Japan
  • Research Site
    Toda-shi, Saitama 335-0023, Japan
  • Research Site
    Otsu-shi, Shiga 520-0113, Japan
  • Research Site
    Bunkyo-ku, Tokyo 113-8421, Japan
  • Research Site
    Bunkyo-ku, Tokyo 113-8519, Japan
  • Research Site
    Chiyoda-ku, Tokyo 101-0041, Japan
  • Research Site
    Chuo-ku, Tokyo 103-0027, Japan
  • Research Site
    Hachioji-shi, Tokyo 192-0918, Japan
  • Research Site
    Itabashi-ku, Tokyo 173-8610, Japan
  • Research Site
    Shinagawa-ku, Tokyo 141-0001, Japan
  • Research Site
    Taito-ku, Tokyo 111-0052, Japan
  • Research Site
    Toshima-ku, Tokyo 171-0021, Japan
09

References and documents

Publications

  • Hirayama A, Yamashita S, Inomata H, Kassahun H, Cyrille M, Ruzza A, Yoshida M, Kiyosue A, Ma Y, Teramoto T. One-Year Efficacy and Safety of Evolocumab in Japanese Patients - A Pooled Analysis From the Open-Label Extension OSLER Studies. Circ J. 2017 Jun 23;81(7):1029-1035. doi: 10.1253/circj.CJ-16-1016. Epub 2017 Mar 29. PubMed 28367845 ↗
  • Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1. PubMed 28249876 ↗
  • Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. PubMed 29353350 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in May 2013, 10 months.

Results were first posted in Oct 2015, 2 years 4 months after primary completion. A results delay was requested in May 2014.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 10 months is above that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2012
First posted
Jul 30, 2012
StartActual
Jul 10, 2012
Primary completionActual
May 14, 2013
Results delay requested
May 12, 2014
Results first posted
Oct 5, 2015
Last update
Nov 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01652703
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 30, 2012
Start date
Jul 10, 2012
Primary completion
May 14, 2013
Results posted
Oct 5, 2015
Last update
Nov 28, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion